Novo Nordisk Invests $1.2 Billion in New Danish Production Facility for Rare Disease Therapies

Investment Amount:
Novo Nordisk is investing $1.2 billion (DKK 8.5 billion) in a new production facility in Odense, Denmark, dedicated to rare disease therapies124.

Facility Details:
The facility will be 430,000 square feet (40,000 square meters) and include a state-of-the-art finished production facility and warehouse, designed to be modular and flexible to accommodate multiple product types within rare diseases, including hemophilia145.

Completion Date:
Construction has begun and is expected to be completed by 2027, creating 400 permanent jobs and up to 1,000 external employment opportunities during construction124.

Sustainability:
The facility will incorporate sustainable features such as solar panels for on-site electricity generation, and the landscape will include reused excess soil, wooden materials, and other sustainable resources to create lakes, forests, and community spaces open to the public12.

Recent Investments:
This investment follows Novo Nordisk's recent $409 million investment in a new quality control laboratory in Hillerød, Denmark, and other significant investments to expand manufacturing capacity globally14.

Sources:

1. https://www.pharmaceuticalcommerce.com/view/novo-nordisk-1-2-billion-new-production-plant

2. https://www.pharmamanufacturing.com/industry-news/news/55249790/novo-nordisk-to-invest-12b-in-new-rare-disease-drug-plant-in-denmark

4. https://www.biospace.com/business/novo-deepens-denmark-commitment-with-1-2b-rare-disease-production-facility

5. https://www.biospace.com/press-releases/novo-nordisk-invests-dkk-8-5-billion-in-new-production-facility-in-odense-denmark